More Physicians Seek Interventional Therapies for Acute and Chronic Pain; Top Pain Doctors Praise New Peripheral Nerve Stimulation System From SPR Therapeutics; Global Neuromodulation Market to Hit $7 Billion by 2018
Pain physicians in the United States are turning to neurostimulation to treat chronic and acute pain in an effort to combat the opioid epidemic. The global neuromodulation devices market is expected to reach $7.07 billion by 2018, up 270 percent from 2011, according to a recent report by Transparency Market Research. Neurostimulation is a drug-free therapy that uses mild electrical pulses to activate and stimulate nerves to achieve pain relief.
“We’re seeing a greater desire among physicians to use drug-free therapies such as neurostimulation for the relief of chronic and acute pain,” said Maria Bennett, SPR® Therapeutics Founder, President and CEO. “Opioids have almost no long-term efficacy data and are known to cause abuse, addiction and death. Neurostimulation is a safe, effective treatment for sustained pain relief.”
The annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes according to a study by the American Pain Society. Currently, opioids are the primary treatment option for moderate-to-severe chronic and acute pain. However, innovative technologies like the FDA-cleared SPRINT™ Percutaneous Peripheral Nerve Stimulation (PNS) System from SPR Therapeutics, are offering physicians important drug-free treatment alternatives as attested to by the physicians below:
“As part of a study, the SPRINT PNS System was used on ten patients who underwent total knee arthroplasty. With SPRINT, patients reported average pain relief of 75 percent. Not only does this therapy help patients immediately with their pain, but by helping patients earlier in the pain continuum, we may be able to prevent acute pain from becoming chronic, which costs our healthcare system billions of dollars annually. SPRINT has the potential to revolutionize the way we treat pain.” — Brian Ilfeld, MD, MS, Professor of Anesthesiology, University of California San Diego.
Read the full release at Market Wired.